en · de · es · fr · pt
faq-desk.peptides1004.com › Faq › Identity And Research Origin — Reference Sheet

Identity And Research Origin — Reference Sheet

By Editorial Desk · published 2025-09-20 · last reviewed 2025-11-03 · Faq

regulatory status is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2025-11-03. Numbers and descriptions here follow the published literature rather than marketing material.

Identity and Research Origin

AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.

Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.

Measurement and Storage Practices

Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.

Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.

Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.

Aod-9604 at a glance

PropertyValueNotes
Molecular classPeptide fragmentCorresponds to hGH residues 176-191
Common synonymsAOD9604, hGH 176-191Also written as AOD-9604
Typical formLyophilized powderOften supplied in sealed vials
SolubilityWater-solubleDissolves in aqueous buffers
Regulatory statusNot approved as drugBanned in sport; varies by country

Regulatory and Analytical Context

Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.

Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.

In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.

Related pages on this site

Background and Molecular Identity

AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.

The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.

Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.

Research and Regulatory Context

Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.

Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.

Regulation and Detection Context

AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.

Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.

Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.

Further detail

The metabolism of drugs is often divided into the following three phases. Phase I: modification, phase II: conjugation, and phase III: excretion. These phases act in concert to detoxify drugs and remove them from cells and eventually from the body. The purpose of phase I is to introduce polar groups that either themselves directly facilitate excretion or to create reactive functional groups. These reactive groups can be conjugated in a phase II reaction with molecules that are recognized by transport proteins. In the last step, transport proteins eliminate the drug conjugate from the body. In phase I, enzymes such as Cytochrome P450 oxidases introduce reactive or polar groups into xenobiotics. These modified compounds are then conjugated to polar compounds in phase II reactions. These reactions are catalyzed by transferase enzymes such as glutathione S-transferases. Finally, in phase III, the conjugated xenobiotics may be further processed, before being recognized by efflux transporters and pumped out of cells. Drug metabolism often converts lipophilic compounds into hydrophilic products that are more readily excreted.

C-4 is very stable and insensitive to most physical shocks. C-4 cannot be detonated by a gunshot or by dropping it onto a hard surface. It does not explode when set on fire or exposed to microwaves. Detonation can be initiated only by a shockwave, such as when a detonator inserted into it is fired. When detonated, C-4 rapidly decomposes to release nitrogen, water and carbon oxides as well as other gases. The detonation proceeds at an explosive velocity of 8,092 m/s (26,550 ft/s). A major advantage of C-4 is that it can easily be molded into any desired shape to change the direction of the resulting explosion. C-4 has high cutting ability. For example, the complete severing of a 36-centimetre (14 in) deep I-beam takes between 680 and 910 g (1.50 and 2.01 lb) of C-4 when properly applied in thin sheets.

Alice in Chains (often abbreviated as AiC) is an American rock band formed in Seattle in 1987. Since 2006, the band's lineup has consisted of vocalist/guitarists Jerry Cantrell and William DuVall, bassist Mike Inez, and drummer Sean Kinney. Original vocalist Layne Staley died in 2002, and former bassist Mike Starr left in 1993. Often associated with grunge music, Alice in Chains' sound and style is rooted in heavy metal. The band is known for its distinctive vocal style, which often included the harmonized vocals between Staley and Cantrell (and later Cantrell and DuVall). Alice in Chains' original lineup consisted of Cantrell, Kinney, Staley, and Starr. They took the name from Staley's previous band, Alice N' Chains. The band rose to international fame as part of the grunge movement of the early 1990s, along with other Seattle bands such as Nirvana, Pearl Jam, and Soundgarden. They broke through on MTV and mainstream rock radio with the single "Man in the Box" (from their 1990 debut album Facelift). After releasing the EP Sap in early 1992, the band achieved major mainstream and commercial success with their follow-up album Dirt later that same year. Dirt contained the popular singles "Rooster" and "Would?", among others. Starr was replaced on bass by Inez in early 1993. The following two records, 1994's Jar of Flies (which included the popular single "No Excuses") and 1995's Alice in Chains (also contained radio hits such as "Heaven Beside You" and "Grind"), both topped the US Billboard 200 chart and earned the band several Grammy Award nominations.

Common treatments to remove contaminants include treatments with ethanol and formaldehyde, the latter of which is very common; ethanol solutions help remove compounds bonded to the alginate, and formaldehyde solutions help prevent enzymatic or microbial reactions. The algae is then treated with an acidic solution to help disrupt cell walls, which converts the alginate salts into insoluble alginic acid; a subsequently applied alkaline solution (pH 9-10), usually sodium carbonate, converts it back into water-soluble sodium alginate, which is then precipitated. It is also possible to extract the alginate directly with an alkaline treatment, but this is less common. Alginic acid is usually precipitated, through different techniques, with either an alcohol (usually ethanol), calcium chloride, or hydrochloric acid. After the alginin is precipitated into a fine paste, it is dried, ground to the desired grain size, and finally purified through a variety of techniques. Commercial alginate for biomedical and pharmaceutical use is extracted and purified through more rigorous techniques, but these are trade secrets.

Sources: en.wikipedia.org

Background from the literature

=== Prostitution === Shortly after giving birth to her second child, Rose began to work as a prostitute, operating from an upstairs room at Cromwell Street and advertising her services in a local contact magazine. Fred encouraged Rose to seek clients in Gloucester's West Indian community through these advertisements. In addition to her prostitution, Rose engaged in casual sex with both male and female lodgers within their household, and individuals Fred encountered via his work. She also bragged to several people that no man or woman could completely satisfy her. When engaging in sexual relations with women, Rose would gradually increase the level of brutality to which she subjected her partner, with acts such as partially asphyxiating her partner or inserting increasingly large dildos into her partner's body. If the woman resisted or expressed any pain or fear, Rose would become greatly excited and typically ask: "Aren't you woman enough to take it?" To many of these women, it became apparent Rose and her husband (who regularly participated in threesomes with his wife and her lovers) took a particular pleasure from taking women beyond their sexual limits—typically via sessions involving bondage. The Wests openly admitted to taking a particular pleasure from any form of sex involving a strong measure of dominance, violence and pain. To cater to these fetishes, they amassed a large collection of bondage and restraining devices, magazines and photographs, later expanding this collection to include videos depicting bestiality and graphic child sexual abuse.

In 16th-century Europe, medical practitioners in army and university settings began to gather information on the cause and manner of death. Ambroise Paré, a French army surgeon, systematically studied the effects of violent death on internal organs. Two Italian surgeons, Fortunato Fidelis and Paolo Zacchia, laid the foundation of modern pathology by studying changes that occurred in the structure of the body as the result of disease. In the late 18th century, writings on these topics began to appear. These included A Treatise on Forensic Medicine and Public Health by the French physician François-Emmanuel Fodéré and The Complete System of Police Medicine by the German medical expert Johann Peter Frank. As the rational values of the Enlightenment era increasingly permeated society in the 18th century, criminal investigation became a more evidence-based, rational procedure − the use of torture to force confessions was curtailed, and belief in witchcraft and other powers of the occult largely ceased to influence the court's decisions. Two examples of English forensic science in individual legal proceedings demonstrate the increasing use of logic and procedure in criminal investigations at the time. In 1784, in Lancaster, John Toms was tried and convicted for murdering Edward Culshaw with a pistol. When the dead body of Culshaw was examined, a pistol wad (crushed paper used to secure powder and balls in the muzzle) found in his head wound matched perfectly with a torn newspaper found in Toms's pocket, leading to the conviction.

If prolonged, or severe, it can cause coma and death regardless of cause. For a person with diabetes, this can be caused by insufficient glucose absorption (e.g. from inadequate insulin) combined with metabolic ketosis. It can lead to diabetic ketoacidosis, a medical emergency. Acute Happens for a limited period of time; abrupt onset; sharp, severe. Adrenal gland An endocrine gland located on top of the human kidney. Secretes adrenaline, one of the primary 'fight or flight' stress hormones, which have substantial counterregulatory effects. Adverse effect A harmful result. Albuminuria release of the protein albumin in urine. As this protein is strongly conserved, this is evidence of abnormal kidney function. Aldose reductase inhibitor Alpha cell one of the types of cell in the pancreas (in areas called the Islets of Langerhans). Alpha cells make and release a hormone called glucagon, which raises the level of glucose (sugar) in the blood. Amino acid a weak acid carbon compound containing carbon, hydrogen, oxygen, and nitrogen. The nitrogenous amine group is characteristic of each. Amino acids are the building blocks of protein and there are about 20 used in the human body, of which about half can be constructed internally. The rest must come in the diet—they are the essential amino acids. Amyotrophy A type of diabetic neuropathy that causes muscle weakness and wasting. Amylin A peptide thought to be involved in beta cell loss in type 2 diabetes. Angiopathy A process that damages the blood vessels.

Sources: en.wikipedia.org

Frequently asked questions

What is AOD-9604?

AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.

Is AOD-9604 the same as growth hormone?

No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.

How is AOD-9604 regulated?

Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.

How is AOD-9604 typically analyzed?

Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.

Network